The Obesity Controversy: Does It Impact Treatment Response in Diffuse Large B-Cell Lymphoma?

Basit Öğe Kaydı
dc.contributor.authorAtak, S.
dc.contributor.authorSerin, I.
dc.contributor.authorDemirel, N.
dc.contributor.authorDogan, E.E.
dc.contributor.authorAydın, D.
dc.contributor.authorNizam, N.
dc.contributor.authorMansuroglu I.
dc.date.accessioned2024-05-19T14:33:30Z
dc.date.available2024-05-19T14:33:30Z
dc.date.issued2023
dc.departmentİstinye Üniversitesien_US
dc.description.abstractBackground: We aimed to investigate the association of body mass index (BMI) with treatment response in patients with DLBCL Material and Methods: Seventy-nine DLBCL subjects were included in this study. Data about patient age, sex, serum LDH level, presence of B symptoms, IPI score, ECOG performance score, disease stage, extranodal involvement, and BMI values at diagnosis were retrieved by retrospective patient record review. Patients were staged according to Ann Arbor classification using CT and/or PET/CT findings, and the presence of B symptoms. Body mass index was calculated by dividing weight in kilograms by height in meters squared (kg/m2). Patients were divided into groups according to their BMI as underweight (BMI? 18.5 kg/m2), normal weight (BMI 18.5-25 kg/m2), overweight (BMI 25-30 kg/m2), and obese (BMI? 30 kg/m2), as defined by the World Health Organization. Results: Patients were divided into four groups according to their BMIs, but because there was only one patient in the underweight group, comparisons were performed between normal-weight, overweight, and obese patients. There was no statistically significant difference between these groups in terms of age, sex, serum LDH level, disease stage, presence of B symptoms, extranodal involvement, ECOG performance score, IPI score and treatment response (p= 0.070, 0.704, 0.325, 0.464, 0.254, 0.152, 0.658, 0.620, and 0.947, respectively) Conclusion: In our study, we showed that BMI has no significant impact on treatment response in patients with DLBCL. © 2023 Tehran University of Medical Sciences.en_US
dc.identifier.doi10.18502/ijhoscr.v17i2.12643
dc.identifier.endpage80en_US
dc.identifier.issn1735-1243
dc.identifier.issue2en_US
dc.identifier.scopus2-s2.0-85159021540en_US
dc.identifier.scopusqualityQ3en_US
dc.identifier.startpage75en_US
dc.identifier.urihttps://doi.org/10.18502/ijhoscr.v17i2.12643
dc.identifier.urihttps://hdl.handle.net/20.500.12713/4255
dc.identifier.volume17en_US
dc.indekslendigikaynakScopusen_US
dc.language.isoenen_US
dc.publisherTehran University of Medical Sciencesen_US
dc.relation.ispartofInternational Journal of Hematology-Oncology and Stem Cell Researchen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.snmz20240519_kaen_US
dc.subjectBody Mass İndexen_US
dc.subjectDiffuse Large B-Cell Lymphomaen_US
dc.subjectObesityen_US
dc.titleThe Obesity Controversy: Does It Impact Treatment Response in Diffuse Large B-Cell Lymphoma?en_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

Scopus İndeksli Yayınlar Koleksiyonu